Literature DB >> 25341580

Gynecologic Cancer Intergroup (GCIG) consensus review for ovarian germ cell tumors.

Jubilee Brown1, Michael Friedlander, Floor J Backes, Philipp Harter, Dennis M O'Connor, Thibault de la Motte Rouge, Domenica Lorusso, Johanne Maenpaa, Jae-Weon Kim, Meghan E Tenney, Michael J Seckl.   

Abstract

Most women diagnosed with malignant ovarian germ cell tumors have curable disease and experience excellent survival with manageable treatment-associated morbidity, related both to tumor biology and improvements in treatment over the last 4 decades. Malignant ovarian germ cell tumors occur predominantly in girls, adolescents, and young women and are often unilateral tumors of early stage, although advanced-stage disease occurs in approximately 30% of patients. Tumors are usually chemosensitive, thereby allowing fertility-sparing surgery in most women with high chance of cure. Differences in practice do exist among providers in various subspecialties and geographic areas. In most settings, collaborative efforts among specialties allow the optimal treatment of women with these rare tumors, and implementation of standard guidelines at an international level should translate to effective clinical trial design, rapid accrual to clinical trials, and universally improved patient outcomes. This consensus guideline represents a summary of recommendations for diagnosis and management that has been agreed upon by cooperative groups worldwide. It builds upon individual publications including previously published summary documents and provides the most current practice standards validated worldwide.

Entities:  

Mesh:

Year:  2014        PMID: 25341580     DOI: 10.1097/IGC.0000000000000223

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  25 in total

Review 1.  Current Strategy for the Treatment of Ovarian Germ Cell Tumors: Role of Extensive Surgery.

Authors:  Jin Li; Xiaohua Wu
Journal:  Curr Treat Options Oncol       Date:  2016-08

2.  Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup (GCIG): clinical trial design for rare ovarian tumours.

Authors:  A F Leary; M Quinn; K Fujiwara; R L Coleman; E Kohn; T Sugiyama; R Glasspool; I Ray-Coquard; N Colombo; M Bacon; A Zeimet; A Westermann; E Gomez-Garcia; D Provencher; S Welch; W Small; D Millan; A Okamoto; G Stuart; K Ochiai
Journal:  Ann Oncol       Date:  2017-04-01       Impact factor: 32.976

3.  Clinical outcome of lymphadenectomy in malignant ovarian germ cell tumors: a systematic review and meta-analysis.

Authors:  Ling Han; Yali Chen; Yana Liu; Ai Zheng; Hengxi Chen
Journal:  Am J Cancer Res       Date:  2022-09-15       Impact factor: 5.942

4.  Ferroptosis-Related Long Noncoding RNAs as Prognostic Biomarkers for Ovarian Cancer.

Authors:  Kaili Wang; Shanshan Mei; Mengcheng Cai; Dongxia Zhai; Danying Zhang; Jin Yu; Zhexin Ni; Chaoqin Yu
Journal:  Front Oncol       Date:  2022-06-09       Impact factor: 5.738

5.  Oncological and Reproductive Outcomes in Patients With Advanced-Stage Ovarian Immature Teratoma: Experience From a Tertiary Center.

Authors:  Dan Wang; Wei Cang; Shan Zhu; Congwei Jia; Dongyan Cao; Jiaxin Yang; Yang Xiang
Journal:  Front Oncol       Date:  2022-06-22       Impact factor: 5.738

Review 6.  Fast-growing immature ovarian teratoma during pregnancy: a case report and a review of the literature.

Authors:  Zuoxi He; Yukun Lu; Chuan Xie
Journal:  BMC Pregnancy Childbirth       Date:  2022-06-27       Impact factor: 3.105

7.  Napabucasin overcomes cisplatin resistance in ovarian germ cell tumor-derived cell line by inhibiting cancer stemness.

Authors:  Silvia Schmidtova; Lambert C J Dorssers; Michal Mego; Lucia Kucerova; Leendert H J Looijenga; Katarina Kalavska; Ad J M Gillis; J Wolter Oosterhuis; Hans Stoop; Svetlana Miklikova; Zuzana Kozovska; Monika Burikova; Katarina Gercakova; Erika Durinikova; Michal Chovanec
Journal:  Cancer Cell Int       Date:  2020-08-03       Impact factor: 5.722

8.  Ovarian cystectomy in the treatment of apparent early-stage immature teratoma.

Authors:  Ting Zhao; Yan Liu; Xiao Wang; Hao Zhang; Yuan Lu
Journal:  J Int Med Res       Date:  2017-01-01       Impact factor: 1.671

9.  Analysis of the genomic landscape of yolk sac tumors reveals mechanisms of evolution and chemoresistance.

Authors:  Xuan Zong; Ying Zhang; Xinxin Peng; Dongyan Cao; Mei Yu; Jinhui Wang; Hongyue Li; Xuejiao Guo; Han Liang; Jiaxin Yang
Journal:  Nat Commun       Date:  2021-06-11       Impact factor: 14.919

10.  High-dose chemotherapy and stem-cell rescue for salvage therapy for relapsed malignant mixed ovarian germ cell tumor: A case report.

Authors:  Sarah Sears; Sareena Singh; Hadi Shojaei; Raymond Redline; Kimberly Resnick
Journal:  Gynecol Oncol Rep       Date:  2017-09-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.